Last reviewed · How we verify
Chemotherapy（pemetrexed/gemcitabine）
Pemetrexed and gemcitabine are antifolate and nucleoside analogue chemotherapy agents that inhibit DNA synthesis by disrupting folate-dependent enzymes and nucleotide metabolism, respectively.
Pemetrexed and gemcitabine are antifolate and nucleoside analogue chemotherapy agents that inhibit DNA synthesis by disrupting folate-dependent enzymes and nucleotide metabolism, respectively. Used for Non-small cell lung cancer (Phase 3 trial), Potentially other solid tumors (investigational).
At a glance
| Generic name | Chemotherapy（pemetrexed/gemcitabine） |
|---|---|
| Also known as | pemetrexed/gemcitabine |
| Sponsor | Shanghai Pulmonary Hospital, Shanghai, China |
| Drug class | Antimetabolite chemotherapy combination |
| Target | Thymidylate synthase, dihydrofolate reductase (pemetrexed); ribonucleotide reductase, DNA polymerase (gemcitabine) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Pemetrexed is a multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, disrupting DNA and RNA synthesis. Gemcitabine is a deoxycytidine analogue that is phosphorylated intracellularly and incorporated into DNA, causing chain termination and apoptosis. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Non-small cell lung cancer (Phase 3 trial)
- Potentially other solid tumors (investigational)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Anemia
- Nausea and vomiting
- Fatigue
- Mucositis
- Hepatotoxicity
- Nephrotoxicity
Key clinical trials
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% (PHASE2)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) (PHASE3)
- Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) (PHASE1, PHASE2)
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) (PHASE2)
- A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) (PHASE3)
- BBO-11818 in Adult Subjects With KRAS Mutant Cancer (PHASE1)
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: